Published in Biotech Business Week, April 11th, 2005
These phase IIa clinical trials will comprise three separate studies, which are designed to evaluate the ability of PEP005 Topical to treat three diseases - AK and superficial and nodular forms of basal cell carcinoma, the most common form of NMSC.
Peplin's Managing Director and CEO Michael Aldridge said the trials were a world first, with leading dermatologists in major metropolitan centers around Australia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.